The ASADR is a module of the Australasian Severe Asthma Registry (ASAR). It aims to examine the characteristics of people initiated on dupilumab (Dupixent) and their responses to treatment in a real-world setting in Australia. The ASADR is a longitudinal, prospective product registry of adult participants newly treated with dupilumab for asthma.
Patient enrolment
Following screening and enrolment, participants will be followed up for up to two years after dupilumab initiation. The aim of this registry study is to examine the characteristics of people initiated on dupilumab and their responses to treatment in a real-world setting in Australia.
If you would like to register your interest or for further information about ASADR/ASAR, contact the TSANZ registries team:
Email: registries@thoracic.org.au
Webpage: https://thoracic.org.au/research-and-awards/australasian-severe-asthma-registry-asar/
ASAR is supported by AstraZeneca, GlaxoSmithKline, Novartis and Sanofi.
If you would like to register your interest or for further information about ASADR/ASAR, contact the TSANZ registries team:
Email: registries@thoracic.org.au
Webpage: https://thoracic.org.au/research-and-awards/australasian-severe-asthma-registry-asar/
ASAR is supported by AstraZeneca, GlaxoSmithKline, Novartis and Sanofi.
